SEC Tracker
Get the app

Myriad Genetics MYGN

Myriad Genetics: quarterly report for the quarter ended Mar 31, 2023

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Myriad Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Kura Oncology KURA public float $496M, Jun 30, 2025
  2. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  3. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. aTYR PHARMA ATYR public float $464M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.